iX Biopharma Says Orion Has Yet to Obtain Nevada Pharmacy Licence

• iX Biopharma clarified Orion lacks a Nevada pharmacy license; its November 10, 2025, disclosure referred to FDA 503B registration.
• The Orion joint venture remains unsigned, with negotiations at an advanced stage.
• The February 2026 US Department of Defense contract for Wafermine development is not dependent on Orion’s facility.
• Orion is one of several manufacturing options for Wafermine under the EUA program; the final pathway requires regulatory and defense authority approval.
• Specialized equipment is on loan at Orion’s facility; it may be relocated if another manufacturing site is selected.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IX Biopharma Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: JF3V63ELITTZVD29) on November 03, 2026, and is solely responsible for the information contained therein.